{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:02Z","timestamp":1792788482352,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81870204"],"award-info":[{"award-number":["81870204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82070366"],"award-info":[{"award-number":["82070366"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical Science and technology development Foundation, Nanjing Department of Health","award":["ZKX19017"],"award-info":[{"award-number":["ZKX19017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>The therapeutic efficacy of single-dose mesenchymal stromal cell (MSC) therapy for heart failure (HF) remains inconsistent. This study aimed to investigate whether infusion with two-dose human umbilical cord MSC (hUCMSCs) could be therapeutically superior to single-dose therapy in a rat model of dilated cardiomyopathy (DCM) and explored the underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Male Sprague\u2013Dawley rats were intraperitoneally injected with doxorubicin (DOX) to establish a DCM model and randomized to intravenously receive single-dose or two-dose hUCMSCs at an interval of 14\u00a0days. Their left ventricular (LV) systolic and diastolic functions were analyzed by echocardiography. The percentages of Th1, Th2, Th17, and Treg cells in the heart, spleen, lymph nodes, and peripheral blood and the levels of serum cytokines in individual rats were analyzed by flow cytometry and cytometric bead assay, respectively. The degrees of cardiac fibrosis and cardiomyocyte apoptosis were examined by histology. The importance of indoleamine 2,3-dioxygenase (IDO), an activator of Treg differentiation, in the therapeutic effect of hUCMSCs on inflammation and heart function of rats was determined after induction of IDO over-expression (IDO-OE) using IFN-\u03b3 (1\u00a0ng\/ml) and TNF-\u03b1 (10\u00a0ng\/ml) stimulation or silencing (IDO-KD) using small interfering RNA (siRNA) technology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with the single dose, two-dose hUCMSCs were more effective in improving LV performance, attenuating cardiac dilation, reducing cardiomyocyte apoptosis and cardiac fibrosis. Two-dose hUCMSC therapy significantly increased Treg number in the heart and peripheral blood, accompanied by increased cardiac IDO expression. Compared with the control hUCMSCs, IDO-OE hUCMSCs significantly enhanced Treg and Th2 cell responses and decreased systemic Th17 cell responses and Th1 cell numbers in the mediastinal lymph nodes. Treatment with IDO-OE hUCMSCs significantly improved LV remodeling and dysfunction. However, treatment with IDO-KD hUCMSCs had opposite effects in rats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Administration of two-dose hUCMSCs has better therapeutic effects than single-dose therapy for inhibiting myocardial inflammation to improve LV function in DCM rats. These effects are associated with upregulating IDO expression and its systemic anti-inflammatory activities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-022-03101-w","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T07:05:52Z","timestamp":1660287952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Infusion of two-dose mesenchymal stem cells is more effective than a single dose in a dilated cardiomyopathy rat model by upregulating indoleamine 2,3-dioxygenase expression"],"prefix":"10.1186","volume":"13","author":[{"given":"Chenyi","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"3101_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurjhf\/hfn043","volume":"11","author":"S Heymans","year":"2009","unstructured":"Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:119\u201329.","journal-title":"Eur J Heart Fail"},{"key":"3101_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCRESAHA.116.308030","volume":"119","author":"SA Dick","year":"2016","unstructured":"Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know? Circ Res. 2016;119:159\u201376.","journal-title":"Circ Res"},{"key":"3101_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1161\/CIRCULATIONAHA.107.759191","volume":"118","author":"SM Dunlay","year":"2008","unstructured":"Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation. 2008;118:625\u201331.","journal-title":"Circulation"},{"key":"3101_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","volume":"17","author":"L Adamo","year":"2020","unstructured":"Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020;17:269\u201385.","journal-title":"Nat Rev Cardiol"},{"key":"3101_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00395-016-0573-2","volume":"111","author":"A Martire","year":"2016","unstructured":"Martire A, Bedada FB, Uchida S, Poling J, Kruger M, Warnecke H, et al. Mesenchymal stem cells attenuate inflammatory processes in the heart and lung via inhibition of TNF signaling. Basic Res Cardiol. 2016;111:54.","journal-title":"Basic Res Cardiol"},{"key":"3101_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejcb.2015.11.003","volume":"95","author":"X Gong","year":"2016","unstructured":"Gong X, Wang P, Wu Q, Wang S, Yu L, Wang G. Human umbilical cord blood derived mesenchymal stem cells improve cardiac function in cTnT(R141W) transgenic mouse of dilated cardiomyopathy. Eur J Cell Biol. 2016;95:57\u201367.","journal-title":"Eur J Cell Biol"},{"key":"3101_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13287-017-0472-y","volume":"8","author":"C Mao","year":"2017","unstructured":"Mao C, Hou X, Wang B, Chi J, Jiang Y, Zhang C, et al. Intramuscular injection of human umbilical cord-derived mesenchymal stem cells improves cardiac function in dilated cardiomyopathy rats. Stem Cell Res Ther. 2017;8:18.","journal-title":"Stem Cell Res Ther"},{"key":"3101_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11010-013-1894-1","volume":"387","author":"Q Yu","year":"2014","unstructured":"Yu Q, Li Q, Na R, Li X, Liu B, Meng L, et al. Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy. Mol Cell Biochem. 2014;387:279\u201385.","journal-title":"Mol Cell Biochem"},{"key":"3101_CR9","first-page":"71","volume":"17","author":"C Zhang","year":"2018","unstructured":"Zhang C, Zhou G, Chen Y, Liu S, Chen F, Xie L, et al. Human umbilical cord mesenchymal stem cells alleviate interstitial fibrosis and cardiac dysfunction in a dilated cardiomyopathy rat model by inhibiting TNFalpha and TGFbeta1\/ERK1\/2 signaling pathways. Mol Med Rep. 2018;17:71\u20138.","journal-title":"Mol Med Rep"},{"key":"3101_CR10","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.transproceed.2019.01.080","volume":"51","author":"C Zhang","year":"2019","unstructured":"Zhang C, Zhou Y, Lai X, Zhou G, Wang H, Feng X, et al. Human umbilical cord mesenchymal stem cells alleviate myocardial endothelial-mesenchymal transition in a rat dilated cardiomyopathy model. Transplant Proc. 2019;51:936\u201341.","journal-title":"Transplant Proc"},{"key":"3101_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1152\/physrev.00019.2015","volume":"96","author":"S Golpanian","year":"2016","unstructured":"Golpanian S, Wolf A, Hatzistergos KE, Hare JM. Rebuilding the damaged heart: mesenchymal stem cells, cell-based therapy, and engineered heart tissue. Physiol Rev. 2016;96:1127\u201368.","journal-title":"Physiol Rev"},{"key":"3101_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCRESAHA.118.313251","volume":"123","author":"M Wysoczynski","year":"2018","unstructured":"Wysoczynski M, Khan A, Bolli R. New paradigms in cell therapy: repeated dosing, intravenous delivery, immunomodulatory actions, and new cell types. Circ Res. 2018;123:138\u201358.","journal-title":"Circ Res"},{"key":"3101_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41418-017-0006-2","volume":"25","author":"G Wang","year":"2018","unstructured":"Wang G, Cao K, Liu K, Xue Y, Roberts AI, Li F, et al. Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells. Cell Death Differ. 2018;25:1209\u201323.","journal-title":"Cell Death Differ"},{"key":"3101_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","volume":"37","author":"DH Munn","year":"2016","unstructured":"Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 2016;37:193\u2013207.","journal-title":"Trends Immunol"},{"key":"3101_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI31178","volume":"117","author":"DH Munn","year":"2007","unstructured":"Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117:1147\u201354.","journal-title":"J Clin Invest"},{"key":"3101_CR16","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1182\/blood-2010-06-288498","volume":"117","author":"RB Sorensen","year":"2011","unstructured":"Sorensen RB, Hadrup SR, Svane IM, Hjortso MC, Thor SP, Andersen MH. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood. 2011;117:2200\u201310.","journal-title":"Blood"},{"key":"3101_CR17","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1161\/CIRCULATIONAHA.120.046789","volume":"142","author":"N Xia","year":"2020","unstructured":"Xia N, Lu Y, Gu M, Li N, Liu M, Jiao J, et al. A unique population of regulatory T cells in heart potentiates cardiac protection from myocardial infarction. Circulation. 2020;142:1956\u201373.","journal-title":"Circulation"},{"key":"3101_CR18","doi-asserted-by":"publisher","first-page":"6079713","DOI":"10.1155\/2020\/6079713","volume":"2020","author":"A Hammer","year":"2020","unstructured":"Hammer A, Sulzgruber P, Koller L, Kazem N, Hofer F, Richter B, et al. The prognostic impact of circulating regulatory T lymphocytes on mortality in patients with ischemic heart failure with reduced ejection fraction. Mediators Inflamm. 2020;2020:6079713.","journal-title":"Mediators Inflamm"},{"key":"3101_CR19","doi-asserted-by":"publisher","first-page":"732794","DOI":"10.3389\/fimmu.2021.732794","volume":"12","author":"Y Lu","year":"2021","unstructured":"Lu Y, Xia N, Cheng X. Regulatory T cells in chronic heart failure. Front Immunol. 2021;12:732794.","journal-title":"Front Immunol"},{"key":"3101_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10616-012-9528-0","volume":"65","author":"YF Han","year":"2013","unstructured":"Han YF, Tao R, Sun TJ, Chai JK, Xu G, Liu J. Optimization of human umbilical cord mesenchymal stem cell isolation and culture methods. Cytotechnology. 2013;65:819\u201327.","journal-title":"Cytotechnology"},{"key":"3101_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/jpi.12357","volume":"61","author":"S Chua","year":"2016","unstructured":"Chua S, Lee FY, Chiang HJ, Chen KH, Lu HI, Chen YT, et al. The cardioprotective effect of melatonin and exendin-4 treatment in a rat model of cardiorenal syndrome. J Pineal Res. 2016;61:438\u201356.","journal-title":"J Pineal Res"},{"key":"3101_CR22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s13287-020-01852-y","volume":"11","author":"E Xiang","year":"2020","unstructured":"Xiang E, Han B, Zhang Q, Rao W, Wang Z, Chang C, et al. Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis. Stem Cell Res Ther. 2020;11:336.","journal-title":"Stem Cell Res Ther"},{"key":"3101_CR23","doi-asserted-by":"publisher","first-page":"e3688","DOI":"10.1161\/CIRCHEARTFAILURE.116.003688","volume":"10","author":"SS Bansal","year":"2017","unstructured":"Bansal SS, Ismahil MA, Goel M, Patel B, Hamid T, Rokosh G, et al. Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circ Heart Fail. 2017;10:e3688.","journal-title":"Circ Heart Fail"},{"key":"3101_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrcardio.2015.169","volume":"13","author":"X Meng","year":"2016","unstructured":"Meng X, Yang J, Dong M, Zhang K, Tu E, Gao Q, et al. Regulatory T cells in cardiovascular diseases. Nat Rev Cardiol. 2016;13:167\u201379.","journal-title":"Nat Rev Cardiol"},{"key":"3101_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1536\/ihj.13-343","volume":"55","author":"N Okamoto","year":"2014","unstructured":"Okamoto N, Noma T, Ishihara Y, Miyauchi Y, Takabatake W, Oomizu S, et al. Prognostic value of circulating regulatory T cells for worsening heart failure in heart failure patients with reduced ejection fraction. Int Heart J. 2014;55:271\u20137.","journal-title":"Int Heart J"},{"key":"3101_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2310\/JIM.0000000000000023","volume":"62","author":"HD Bas","year":"2014","unstructured":"Bas HD, Baser K, Yavuz E, Bolayir HA, Yaman B, Unlu S, et al. A shift in the balance of regulatory T and T helper 17 cells in rheumatic heart disease. J Investig Med. 2014;62:78\u201383.","journal-title":"J Investig Med"},{"key":"3101_CR27","doi-asserted-by":"publisher","first-page":"e13537","DOI":"10.1111\/apha.13537","volume":"230","author":"M Lu","year":"2020","unstructured":"Lu M, Qin X, Yao J, Yang Y, Zhao M, Sun L. Th17\/Treg imbalance modulates rat myocardial fibrosis and heart failure by regulating LOX expression. Acta Physiol (Oxf). 2020;230:e13537.","journal-title":"Acta Physiol (Oxf)"},{"key":"3101_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/gut.2009.185108","volume":"59","author":"G Matteoli","year":"2010","unstructured":"Matteoli G, Mazzini E, Iliev ID, Mileti E, Fallarino F, Puccetti P, et al. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory\/T effector cell balance and oral tolerance induction. Gut. 2010;59:595\u2013604.","journal-title":"Gut"},{"key":"3101_CR29","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(09)62023-7","volume":"375","author":"JL Jefferies","year":"2010","unstructured":"Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet. 2010;375:752\u201362.","journal-title":"Lancet"},{"key":"3101_CR30","doi-asserted-by":"publisher","first-page":"7447","DOI":"10.3390\/ijms22147447","volume":"22","author":"F Gubert","year":"2021","unstructured":"Gubert F, Da SJ, Vasques JF, de Jesus GR, Martins RS, de Sa M, et al. Mesenchymal stem cells therapies on fibrotic heart diseases. Int J Mol Sci. 2021;22:7447.","journal-title":"Int J Mol Sci"},{"key":"3101_CR31","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/CIRCRESAHA.117.310712","volume":"121","author":"J Bartolucci","year":"2017","unstructured":"Bartolucci J, Verdugo FJ, Gonzalez PL, Larrea RE, Abarzua E, Goset C, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1\/2 randomized controlled trial (RIMECARD trial [Randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circ Res. 2017;121:1192\u2013204.","journal-title":"Circ Res"},{"key":"3101_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fimmu.2014.00148","volume":"5","author":"E Eggenhofer","year":"2014","unstructured":"Eggenhofer E, Luk F, Dahlke MH, Hoogduijn MJ. The life and fate of mesenchymal stem cells. Front Immunol. 2014;5:148.","journal-title":"Front Immunol"},{"key":"3101_CR33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1161\/CIRCRESAHA.117.310710","volume":"120","author":"R Bolli","year":"2017","unstructured":"Bolli R. Repeated cell therapy: a paradigm shift whose time has come. Circ Res. 2017;120:1072\u20134.","journal-title":"Circ Res"},{"key":"3101_CR34","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1038\/s41598-018-20686-6","volume":"8","author":"K Miteva","year":"2018","unstructured":"Miteva K, Pappritz K, Sosnowski M, El-Shafeey M, Muller I, Dong F, et al. Mesenchymal stromal cells inhibit NLRP3 inflammasome activation in a model of Coxsackievirus B3-induced inflammatory cardiomyopathy. Sci Rep. 2018;8:2820.","journal-title":"Sci Rep"},{"key":"3101_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00395-020-0800-8","volume":"115","author":"J Wang","year":"2020","unstructured":"Wang J, Chen Z, Dai Q, Zhao J, Wei Z, Hu J, et al. Intravenously delivered mesenchymal stem cells prevent microvascular obstruction formation after myocardial ischemia\/reperfusion injury. Basic Res Cardiol. 2020;115:40.","journal-title":"Basic Res Cardiol"},{"key":"3101_CR36","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1161\/CIRCRESAHA.116.309819","volume":"120","author":"AJ Kanelidis","year":"2017","unstructured":"Kanelidis AJ, Premer C, Lopez J, Balkan W, Hare JM. Route of delivery modulates the efficacy of mesenchymal stem cell therapy for myocardial infarction: a meta-analysis of preclinical studies and clinical trials. Circ Res. 2017;120:1139\u201350.","journal-title":"Circ Res"},{"key":"3101_CR37","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1002\/jcb.26168","volume":"118","author":"AS Abd","year":"2017","unstructured":"Abd AS, Hussein S, Hasan MM, Deraz R, Hussein WF, Sabik L. Functional and structural assessment of the effect of human umbilical cord blood mesenchymal stem cells in doxorubicin-induced cardiotoxicity. J Cell Biochem. 2017;118:3119\u201329.","journal-title":"J Cell Biochem"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-022-03101-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-022-03101-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-022-03101-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T07:09:27Z","timestamp":1660288167000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-022-03101-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3101"],"URL":"https:\/\/doi.org\/10.1186\/s13287-022-03101-w","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"29 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human-derived materials were approved by the Research Ethics Board of Nanjing Drum Tower Hospital (Permit Number: 2017-161-01). Animal experiments were performed, according to the guidelines of the National Institutes of Health and approved by the Institutional Ethics Committee of Nanjing Drum Tower Hospital (Approval No. 20210116).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}